Trial Profile
A phase III, double-blind, insulin-combination therapy study of imeglimin (TIMES 3)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Imeglimin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms TIMES 3
- Sponsors Poxel; Sumitomo Dainippon Pharma
- 18 Apr 2022 Results assessing efficacy and safety of imeglimin for up to 52 weeks as combination therapy with insulin in Japanese patients with type 2 diabetes, published in the Diabetes, Obesity and Metabolism.
- 22 Mar 2022 According to Poxel media release, data from this study were published at Diabetes Obesity and Metabolism in Jan 2021.
- 23 Jun 2021 According to Poxel media release, a new drug application for TWYMEEG Tablets 500mg3 for the treatment of type 2 diabetes, was approved in Japan supported by positive results from the Phase 3 TIMES program